Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866072 | 1.00 | PDE10A (0.50) | PDE10ACXCR4GAAMAPTHTT | |
| SCHEMBL29228864 | 0.84 | PDE10A (0.55) | PDE10A | |
| SCHEMBL6475308 | 0.83 | GAA (0.51) | PDE10ACXCR4GAAHTTPIK3CD | |
| SCHEMBL29227340 | 0.83 | PDE10A (0.50) | PDE10ACXCR4GAAMAPTHTT | |
| SCHEMBL10272910 | 0.83 | PDE10A (0.53) | PDE10ACXCR4GAAHTTPOLB | |
| SCHEMBL1303138 | 0.83 | PDE10A (0.50) | PDE10ACXCR4GAAMAPTHTT | |
| SCHEMBL29907771 | 0.83 | PDE10A (0.50) | PDE10ACXCR4GAAMAPTHTT | |
| SCHEMBL20548111 | 0.83 | PDE10A (0.54) | PDE10A | |
| SCHEMBL6843345 | 0.82 | GAA (0.59) | PDE10ACXCR4GAAMAPTHTT | |
| SCHEMBL10154077 | 0.80 | PDE10A (0.50) | PDE10ACXCR4GAAHTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835712-A | Synthesis method of epinastine | 重庆恩联生物科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| CN-1474803-B | Amide derivatives and their use for the preparation of medicaments | MITSUBISHI TANABE PHARMA CORP | 2012-11-21 | — | — | CN | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| CN-102050758-A | Novel amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| CN-1474803-A | Novel amide derivative and medical use thereof | ������ҩ��ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | PDE10A 2576/4885CXCR4 495/4885GAA 3289/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | PDE10A 2513/4885CXCR4 653/4885GAA 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.